Intersects of EYE with the Immunization Agenda 2030 (IA2030) and implications

22 October 2021

Caption: Nigeria: 2020 Yellow fever response in Delta State launch of the YF PMVC by the Delta state Governor, Nigeria
In response to a request from the EYE Leadership Group (LG), an ad hoc task team (TT) with representation from core partners and stakeholders was created to:

1. **Identify areas of intersect of EYE Strategy with the IA2030**
2. **Identify opportunities and areas of potential high strategic return**
3. **initiate dialogue on potential exit strategy for the EYE Strategy beyond 2026**

Findings from group discussions were analysed by thematic area and presented to the EYE Programme Management Group (PMG) for feedback.
ELIMINATE YELLOW FEVER EPIDEMICS

IA2030
“A world where everyone, everywhere, at every age, fully benefits from vaccines for good health and well-being”

The EYE partnership aims to
- **SO 1: Protect at-risk populations** (vaccination, risk prioritization)
- **SO 2: Prevent international spread** (urban readiness, at-risk workers, IHR)
- **SO 3: Control outbreaks rapidly** (surveillance, Dx, international samples transport, emergency vaccines, response)

Competencies for success
- Governance
- Political commitment at all levels
- Improved YF vaccine supply
- Synergies with other programmes and sectors
- Research and development for better tools and practices
Findings & Next Steps

IA2030/EYE Strategy ad hoc Task Team activities

- Mapped intersects between EYE and each of the IA2030 Strategic Priorities (SP)
- Consultation with task team, associated networks and with EYE PMG for perspectives on areas with greatest yield
- Identify working groups could provide the highest value for EYE & should be prioritized for engagement
- Where PMG members felt they/ their organization could contribute and complementary linkages
- Development of summary report with proposed priority working groups for EYE engagements
- Development of complementary draft briefing notes
- PMG reviewed iteratively, most recent session 13 October 2021
Findings & Next Steps

Way forward

• Matrix of IA2030 working groups (WG) and respective linkage to EYE, to be further populated as groups evolve. Priority groups include Coordination // Partnership Council (LG level engagement), Disease Specific WG, Commitment & Demand WG, Lifecourse & Integration WG, Outbreaks & Emergencies WG.

• Refinement of tailored briefings summarizing EYE priorities for IA2030 working groups.

• Quarterly updates to PMG from priority working groups with EYE network participation + ad hoc as necessary.

Anticipated challenges

• Regarding updates on IA2030 to the EYE PMG, concerns were highlighted by PMG members regarding the rapidity/momentum with which some IA2030 working groups and their activities would evolve, as they might not be able to have relevant updates to share if these groups do not end up meeting frequently or their activities do not progress.

• From a Secretariat standpoint, as the EYE strategy is draws closer to its mid-term (February 2022) with only 5 years left, it would be important to leverage the IA2030 components that will progress rapidly, while at the same time avoiding delays to EYE implementation from any IA2030 areas that lack momentum.
Summary highlights EYE Strategy / IA2030 existing cross-representation

<table>
<thead>
<tr>
<th>MAPPING OF EYE PMG REPRESENTATION ACROSS IA2030 WORKING GROUPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA2030 WORKING GROUP</td>
</tr>
<tr>
<td>Coordination Group/Partnership Council (LG level engagement)</td>
</tr>
<tr>
<td>Disease-specific WG</td>
</tr>
<tr>
<td>Commitment and Demand WG (SP2)</td>
</tr>
<tr>
<td>Life course and Integration WG (SP4)</td>
</tr>
<tr>
<td>Outbreaks and Emergencies WG (SP5)</td>
</tr>
<tr>
<td>Coverage and Equity WG (SP3)</td>
</tr>
<tr>
<td>Research and Innovation WG (SP7)</td>
</tr>
<tr>
<td>PHC/UHC WG (SP1)</td>
</tr>
</tbody>
</table>
Thank you for your partnership

For further information
https://www.who.int/initiatives/eye-strategy
eye.strategy@who.int

Follow us on: Twitter | Facebook | LinkedIn | YouTube